Duplicate publication bias weakens the validity of meta-analysis of immunosuppression after transplantation
- PMID: 29093629
- PMCID: PMC5656468
- DOI: 10.3748/wjg.v23.i39.7198
Duplicate publication bias weakens the validity of meta-analysis of immunosuppression after transplantation
Abstract
Duplicate publication can introduce significant bias into a meta-analysis if studies are inadvertently included more than once. Many studies are published in more than one journal to maximize readership and impact of the study findings. Inclusion of multiple publications of the same study within a meta-analysis affords inappropriate weight to the duplicated data if reports of the same study are not linked together. As studies which have positive findings are more likely to be published in multiple journals this leads to a potential overestimate of the benefits of an intervention. Recent advances in immunosuppression strategies following liver transplantation have led to many studies investigating immunosuppressive regimes including immunosuppression monotherapy. In this letter we focus on a recently published meta-analysis by Lan et al investigating studies assessing immunosuppression monotherapy for liver transplantation. The authors claim to have identified fourteen separate randomised studies investigating immunosuppression monotherapy. Seven of the references appear to relate to only three studies which have been subject to duplicate publication. Several similarities can be identified in each of the duplicate publications including similar authorship, identical immunosuppression regimes, identical dates of enrolment and citation of the original publication in the subsequent manuscripts. We discuss the evidence of the duplicate publication inclusion in the meta-analysis.
Keywords: Bias; Duplicate publication; Immunosuppression; Liver transplantation; Meta-analysis.
Conflict of interest statement
Conflict-of-interest statement: The authors have no conflict of interest to report.
Comment on
-
Efficacy of immunosuppression monotherapy after liver transplantation: a meta-analysis.World J Gastroenterol. 2014 Sep 14;20(34):12330-40. doi: 10.3748/wjg.v20.i34.12330. World J Gastroenterol. 2014. PMID: 25232269 Free PMC article. Review.
References
-
- Samonakis DN, Mela M, Quaglia A, Triantos CK, Thalheimer U, Leandro G, Pesci A, Raimondo ML, Dhillon AP, Rolles K, et al. Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis. Transpl Infect Dis. 2006;8:3–12. - PubMed
-
- Manousou P, Samonakis D, Cholongitas E, Patch D, O’Beirne J, Dhillon AP, Rolles K, McCormick A, Hayes P, Burroughs AK. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transpl. 2009;15:1783–1791. - PubMed
-
- Moench C, Barreiros AP, Schuchmann M, Bittinger F, Thiesen J, Hommel G, Kraemer I, Otto G. Tacrolimus monotherapy without steroids after liver transplantation--a prospective randomized double-blinded placebo-controlled trial. Am J Transplant. 2007;7:1616–1623. - PubMed
-
- Weiler N, Thrun I, Hoppe-Lotichius M, Zimmermann T, Kraemer I, Otto G. Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial. Transplantation. 2010;90:1562–1566. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials